Iovance Biotherapeutics Inc [IOVA] stock prices are up 11.66% to $2.49 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IOVA shares have gain 23.88% over the last week, with a monthly amount glided 22.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on July 15, 2025, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1 for it. Previously, UBS downgraded its rating to Neutral on May 16, 2025, and kept the price target unchanged to $2. On May 12, 2025, downgrade downgraded it’s rating to Hold. Citizens JMP downgraded its rating to a Mkt Perform. UBS initiated its recommendation with a Buy and recommended $17 as its price target on October 24, 2024. Piper Sandler downgraded its rating to Neutral for this stock on July 29, 2024, and downed its price target to $10. In a note dated November 20, 2023, Goldman initiated an Buy rating and provided a target price of $12 on this stock.
The stock price of Iovance Biotherapeutics Inc [IOVA] has been fluctuating between $1.64 and $12.51 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $2.49 at the most recent close of the market. An investor can expect a potential return of 60.64% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
The Iovance Biotherapeutics Inc [NASDAQ:IOVA] reported sales of 212.68M for trailing twelve months, representing a surge of 6798.46%. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -1.88%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Iovance Biotherapeutics Inc [NASDAQ:IOVA]’s Current Ratio is 4.18. In addition, the Quick Ratio stands at 3.64 and the Cash Ratio stands at 1.4. Considering the valuation of this stock, the price to sales ratio is 3.91, the price to book ratio is 1.08.
Transactions by insiders
Recent insider trading involved Kirby Daniel Gordon, Chief Commercial Officer, that happened on Jun 05 ’25 when 30000.0 shares were purchased. Chief Regulatory Officer, Puri Raj K. completed a deal on May 23 ’25 to buy 5600.0 shares. Meanwhile, Interim CEO & General Counsel Vogt Frederick G bought 25000.0 shares on May 14 ’25.
